Literature DB >> 18241620

High-density lipoprotein: antioxidant and anti-inflammatory properties.

Mohamad Navab1, Roger Yu, Nima Gharavi, William Huang, Navid Ezra, Ali Lotfizadeh, G M Anantharamaiah, Nima Alipour, Brian J Van Lenten, Srinivasa T Reddy, Daniel Marelli.   

Abstract

The ability of high-density lipoprotein (HDL) to promote cholesterol efflux is an important component of its ability to protect against cardiovascular disease. In addition, the anti-inflammatory properties of HDL are important as well. As part of the innate immune system, HDL appears to have evolved to increase inflammation in the presence of an acute phase response but to inhibit inflammation in the absence of an acute phase response. In a study of humans with coronary heart disease, it was found that the patients who had proinflammatory HDL prior to statin therapy (and half of them despite a profound decrease in plasma lipids following statin therapy) continued to have proinflammatory HDL. Anti-inflammatory HDL was effective in promoting cholesterol efflux whereas proinflammatory HDL was relatively weak in its ability to promote cholesterol efflux. Oxidative alterations of the main protein of HDL, apolipoprotein A-I, impaired its capacity to promote cholesterol efflux from monocyte macrophages. Therefore, HDL composition, structure, and function appear to be more crucial than HDL cholesterol concentrations in determining risk for cardiovascular disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18241620     DOI: 10.1007/s11883-007-0026-3

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  25 in total

1.  On evolutionary biology, inflammation, infection, and the causes of atherosclerosis.

Authors:  Paul M Ridker
Journal:  Circulation       Date:  2002-01-01       Impact factor: 29.690

2.  Statins promote potent systemic antioxidant effects through specific inflammatory pathways.

Authors:  Mehdi H Shishehbor; Marie-Luise Brennan; Ronnier J Aviles; Xiaoming Fu; Marc S Penn; Dennis L Sprecher; Stanley L Hazen
Journal:  Circulation       Date:  2003-07-14       Impact factor: 29.690

3.  When good cholesterol goes bad.

Authors:  Alan M Fogelman
Journal:  Nat Med       Date:  2004-09       Impact factor: 53.440

Review 4.  HDL and the inflammatory response induced by LDL-derived oxidized phospholipids.

Authors:  M Navab; J A Berliner; G Subbanagounder; S Hama; A J Lusis; L W Castellani; S Reddy; D Shih; W Shi; A D Watson; B J Van Lenten; D Vora; A M Fogelman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-04       Impact factor: 8.311

5.  Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy.

Authors:  Mehdi H Shishehbor; Ronnier J Aviles; Marie-Luise Brennan; Xiaoming Fu; Marlene Goormastic; Gregory L Pearce; Noyan Gokce; John F Keaney; Marc S Penn; Dennis L Sprecher; Joseph A Vita; Stanley L Hazen
Journal:  JAMA       Date:  2003-04-02       Impact factor: 56.272

6.  Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures.

Authors:  B J Van Lenten; S Y Hama; F C de Beer; D M Stafforini; T M McIntyre; S M Prescott; B N La Du; A M Fogelman; M Navab
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

7.  Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages.

Authors:  Lemin Zheng; Megan Settle; Gregory Brubaker; Dave Schmitt; Stanley L Hazen; Jonathan D Smith; Michael Kinter
Journal:  J Biol Chem       Date:  2004-10-21       Impact factor: 5.157

8.  C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease.

Authors:  John Danesh; Jeremy G Wheeler; Gideon M Hirschfield; Shinichi Eda; Gudny Eiriksdottir; Ann Rumley; Gordon D O Lowe; Mark B Pepys; Vilmundur Gudnason
Journal:  N Engl J Med       Date:  2004-04-01       Impact factor: 91.245

9.  Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein.

Authors:  M Navab; S S Imes; S Y Hama; G P Hough; L A Ross; R W Bork; A J Valente; J A Berliner; D C Drinkwater; H Laks
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

10.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

View more
  19 in total

1.  Identification of potential serum markers for endometrial cancer using protein expression profiling.

Authors:  Masashi Takano; Yoshihiro Kikuchi; Takayoshi Asakawa; Tomoko Goto; Tsunekazu Kita; Kazuya Kudoh; Junzo Kigawa; Noriaki Sakuragi; Masaru Sakamoto; Toru Sugiyama; Nobuo Yaegashi; Hiroshi Tsuda; Hiroshi Seto; Mieko Shiwa
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-16       Impact factor: 4.553

2.  Exchange of apolipoprotein A-I between lipid-associated and lipid-free states: a potential target for oxidative generation of dysfunctional high density lipoproteins.

Authors:  Giorgio Cavigiolio; Ethan G Geier; Baohai Shao; Jay W Heinecke; Michael N Oda
Journal:  J Biol Chem       Date:  2010-04-12       Impact factor: 5.157

3.  Apolipoprotein A-I mimetic 4F alters the function of human monocyte-derived macrophages.

Authors:  Lesley E Smythies; C Roger White; Akhil Maheshwari; M N Palgunachari; G M Anantharamaiah; Manjula Chaddha; Ashish R Kurundkar; Geeta Datta
Journal:  Am J Physiol Cell Physiol       Date:  2010-03-10       Impact factor: 4.249

4.  Oxidation of methionine residues in human apolipoprotein A-I generates a potent pro-inflammatory molecule.

Authors:  Andrzej Witkowski; Sonia Carta; Rui Lu; Shinji Yokoyama; Anna Rubartelli; Giorgio Cavigiolio
Journal:  J Biol Chem       Date:  2019-01-11       Impact factor: 5.157

5.  High-density lipoprotein: NO failure in heart failure.

Authors:  Ali Javaheri; Daniel J Rader
Journal:  Circ Res       Date:  2013-12-06       Impact factor: 17.367

6.  High-density lipoprotein inhibits serum amyloid A-mediated reactive oxygen species generation and NLRP3 inflammasome activation.

Authors:  Preetha Shridas; Maria C De Beer; Nancy R Webb
Journal:  J Biol Chem       Date:  2018-07-05       Impact factor: 5.157

7.  Serum C-reactive protein levels in pre-dialysis chronic kidney disease patientsin southern Nigeria.

Authors:  Oluseyi A Adejumo; Enajite I Okaka; Chimezie G Okwuonu; Ikponmwosa O Iyawe; Oluwole O Odujoko
Journal:  Ghana Med J       Date:  2016-03

8.  Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial.

Authors:  Nirupa R Matthan; Nancy Resteghini; Michele Robertson; Ian Ford; James Shepherd; Chris Packard; Brendan M Buckley; J Wouter Jukema; Alice H Lichtenstein; Ernst J Schaefer
Journal:  J Lipid Res       Date:  2010-01       Impact factor: 5.922

9.  Regulation of pattern recognition receptors by the apolipoprotein A-I mimetic peptide 4F.

Authors:  C Roger White; Lesley E Smythies; David K Crossman; Mayakonda N Palgunachari; G M Anantharamaiah; Geeta Datta
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-09-13       Impact factor: 8.311

10.  Higher circulating levels of OxLDL % of LDL are associated with subclinical atherosclerosis in female patients with systemic lupus erythematosus.

Authors:  Hamada Mohammad Ahmad; Esmat M Sarhan; Usama Komber
Journal:  Rheumatol Int       Date:  2013-10-08       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.